Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Quantitation of 4,4'-methylene diphenyl diisocyanate human serum albumin adducts.

Authors
Luna-LG; Green-BJ; Zhang-F; Arnold-SM; Siegel-PD; Bartels-MJ
Source
Toxicol Rep 2014 Oct; 1:743-751
NIOSHTIC No.
20045533
Abstract
4,4'-Methylene diphenyl diisocyanate (herein 4,4'-MDI) is used in the production of polyurethane foams, elastomers, coatings, adhesives and the like for a wide range of commercial products. Occupational exposure to MDI levels above current airborne exposure limits can elicit immune mediated hypersensitivity reactions such as occupational asthma in sensitive individuals. To accurately determine exposure, there has been increasing interest in developing analytical methods to measure internal biomarkers of exposure to MDI. Previous investigators have reported methodologies for measuring MDI diamine metabolites and MDI-Lysine (4,4'-MDI-Lys) adducts. The purpose of this study was to develop and validate an ultra performance liquid chromatography isotope dilution tandem mass spectrometry (UPLC-ID/MS/MS) quantitation method via a signature peptide approach to enable biomonitoring of 4,4'-MDI adducted to human serum albumin (HSA) in plasma. Amurine, anti-4,4'-MDI monoclonal IgM antibody was bound to magnetic beads and utilized for enrichment of the MDI adducted HSA. Following enrichment, trypsin digestion was performed to generate the expected 414 site (primary site of adduction) 4,4'-MDI-adducted HSA signature peptide that was quantified by UPLC-ID/MS/MS. An Agilent 6530UPLC/quadrupole time of flight MS (QTOF) system was utilized for intact adducted protein analysis and an Agilent 6490 UPLC/MS/MS system operated in multiple reaction monitoring (MRM) mode was utilized for quantification of the adducted signature peptidebiomarker both for in chemico and worker serum samples. Worker serum samples were initially screened utilizing the previously developed 4,4'-MDI-Lys amino acid method andresults showed that 12 samples were identified as quantifiable for 4,4'-MDI-Lys adducts.The signature peptide adduct approach was applied to the 12 worker samples identified asquantifiable for 4,4-MDI-Lys adducts. Results indicated no positive results were obtainedabove the quantification limit by the signature peptide approach. If the 414 site of lysineadduction accounted for 100% of the 4,4'-MDI adductions in the signature peptide adductapproach, the three highest quantifiable samples by the 4,4'-MDI-Lys method should haveat least been detectable by the signature peptide method. Results show that although the4,4'-MDI signature peptide approach is more selective, it is 18 times less sensitive thanthe 4,4'-MDI-Lys method, thus limiting the ability to detect adduct levels relative to the4,4'-MDI-Lys amino acid method.
Keywords
Methyl-compounds; Polyurethane-foams; Coatings; Adhesives; Airborne-particles; Bronchial-asthma; Biomarkers; Metabolites; Liquid-chromatography; Mass-spectrometry; Analytical-processes; Author Keywords: MDI; Adduct; Mass spectrometry; Diisocyanates; Biomarkers
CAS No.
101-68-8
Publication Date
20141004
Document Type
Journal Article
Email Address
Luna@dow.com
Fiscal Year
2015
NTIS Accession No.
NTIS Price
ISSN
2214-7500
NIOSH Division
HELD
Source Name
Toxicology Reports
State
GA; WV
TOP